Immunic Therapeutics: Funding, Investors & Team (Oct 2026)
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Immunic Therapeutics has raised $545M across 4 funding rounds on record, the most recent an undisclosed round of $400M announced in Feb 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immunic Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Immunic Therapeutics Funding Rounds
Immunic Therapeutics raised $60.0M in a Post-IPO Equity announced in Oct 2022.
1.3 years later, an undisclosed round of $80.0M was announced in Jan 2024.
1.3 years later, an undisclosed round of $5.1M was announced in Apr 2025.
10 months later, an undisclosed round of $400M was announced in Feb 2026.
Immunic Therapeutics Founders and Leadership Team
Contact details for the Immunic Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Immunic Therapeutics Funding Compared to Other Biotechnology Startups
Immunic Therapeutics' latest round of $400M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immunic Therapeutics in Biotechnology and New York
Companies Similar to Immunic Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Immunic Therapeutics Funding FAQs
What does Immunic Therapeutics do?
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
How much funding has Immunic Therapeutics raised?
Immunic Therapeutics has raised $545M across 4 rounds on record. The most recent is an undisclosed round of $400M announced in Feb 2026.
When did Immunic Therapeutics last raise funding?
Immunic Therapeutics' most recent funding round on record is an undisclosed round of $400M, announced in Feb 2026.
Who founded Immunic Therapeutics?
FundedIQ lists Andreas Muehler (Founder) at Immunic Therapeutics.
Who is the CEO of Immunic Therapeutics?
Daniel Vitt is listed as CEO at Immunic Therapeutics.
Where is Immunic Therapeutics headquartered?
Immunic Therapeutics is based in New York, United States.
How many employees does Immunic Therapeutics have?
Immunic Therapeutics is in the 51-100 employee band.
How does Immunic Therapeutics' funding compare to other Biotechnology startups?
Immunic Therapeutics' latest round of $400M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Immunic Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immunic Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.